Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.

Long-term PPI use does not pose increased fracture risk

16 Jan 2017

Proton pump inhibitor (PPI) therapy does not contribute to increased risk of fractures, with a new study suggesting that its long-term use has no effect on bone mineral density (BMD) or bone strength.

Researchers looked at 52 long-term (≥5 years) PPI users and 52 individuals who had no PPI exposure in the previous 5 years  to determine if long-term PPI induced structural changes in bone independent of areal BMD.

Assessments of areal BMD, volumetric BMD and markers of bone metabolism were performed using dual photon X-ray absorptiometry and three-dimensional quantitative computed tomography. Measures of bone strength such as buckling ratio and section modulus were examined and compared between the groups of PPI users and nonusers.

The results for standard BMD, volumetric BMD and markers of bone mineral density did not differ significantly between the PPI and non-PPI groups.

Likewise, there were no significant between-group differences observed in the measures of bone strength.

The findings show that there is no association between long-term PPI use and any changes in BMD or bone strength that may predispose users to an increased fracture risk.

Researchers said the data provided further evidence that the association between PPI use and fracture was not causal.

Osteoporosis occurs more frequently in women than men, with osteoporotic fractures being associated with significant morbidity and mortality. These fractures translate to high costs, in terms of healthcare costs and lost wages. Multiple medications—including corticosteroids, selective serotonin reuptake inhibitors, anticonvulsants, thiazolinediones, aromatase inhibitors and antiandrogen therapies—have been implicated as contributing to increased risk of fragility fractures. [Osteoporos Int 2013;24:1161–1168]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 May 2016
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Rachel Soon, 12 Dec 2018

MIMS Pharmacist presents an overview of superoxide dismutase (SOD) and its role in resisting the effects of oxidative stress and aging.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

01 Mar 2018
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.